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Objective: Screening for lung cancer will discover many nodules of indeterminate
pathology. Observation has the theoretic risk of permitting dissemination of a
localized cancer and worsening prognosis, whereas immediate evaluation of benign
conditions generates morbidity and cost. This study was conducted to assess the
effect of delay in surgical intervention on survival for patients with early stage
non–small cell lung cancer.
Methods: Records for patients with resected pathologic stage I and II non–small cell
lung cancer (1989-1999) were abstracted for patient age, race, sex, medical history,
date of presentation, date and type of surgical treatment, pathologic stage, and date
of death or last follow-up. Kaplan-Meier survival analysis was performed to test for
the effect of delay (time from presentation to surgical intervention) on survival.
Results: Eighty-four patients were identified. Median age was 66 years, median
preoperative interval was 82 days (range, 1-641 days), and median follow-up was
3.3 years (range, 5 days-11.9 years). Median survival was 3.7 years. Overall 5-year
survival was 40%; disease-specific 5-year survival was 63%. Log-rank analysis of
the effect of delay on overall survival generated a P value of .54, with an estimated
hazard ratio for a 90-day delay of 1.06 (95% confidence interval, 0.87-1.30).
Conclusions: For this population, we were unable to detect a significant effect of
delay on prognosis. Although these results suggest that the risk of judicious
observation of indeterminate pulmonary nodules might be low, the 95% confidence
interval is broad. Larger sample sizes are needed to reach definitive conclusions.
Renewed interest in lung cancer screening has led to the discovery ofindeterminate pulmonary nodules in a large number of patients whoare at risk for lung cancer. Management of these patients dependson knowing the risk associated with observation of cancerouslesions, but there is little evidence to help us understand the trueeffect of delay on prognosis.
Prompt evaluation and resection are the cornerstones of therapy for patients with
a clinical suspicion of early stage non–small cell lung cancer (NSCLC).1 Delay
raises the uncomfortable specter of a lost opportunity for cure. Improvements in
diagnostic studies, such as fine-needle aspiration cytology and positron emission
tomography, tempt us with the prospect of a quick, less-invasive diagnosis, and the
threshold for performing diagnostic wedge resections has been lowered by the
introduction of video-assisted techniques. Yet although these factors make it easier
to proceed quickly to resection, for patients with benign conditions, they incur cost
and morbidity that might have been avoided had a course of observation been
chosen instead.
Fundamental tumor biology suggests that delay between presentation and resec-
tion might have a minimal effect on prognosis. Lung tumors large enough to be
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detected by means of standard chest radiography (1 cm in
diameter) contain approximately 109 cells and therefore
have undergone approximately 30 cell doublings.2 Studies
of tumor biology reveal that doubling times for squamous
cell carcinomas and adenocarcinomas are approximately 88
and 161 days, respectively.2 Thus even lung cancers barely
detectable by means of chest radiography might have been
present for as long as 7 years. The increased sensitivity of
spiral computed tomography (CT) decreases the detection
threshold to approximately 5 mm in diameter, but this
translates into a saving of only 3 doubling times or 10% of
the tumor’s life span. Hence there is considerable opportu-
nity for the cancer to disseminate before its detection by
even the most sensitive of current technologies.
Tumor size represents a convenient marker for disease
progression, but for an individual patient, growth of his or
her tumor during a period of observation before surgical
intervention might have little clinical significance. It is
known that patients with larger tumors (3 cm in diameter)
fare worse than do patients with smaller tumors,3-5 but it is
not known whether the prognosis for an individual patient
worsens if his or her small tumor is allowed to grow during
a brief period of observation. Tumor dissemination, not
tumor size, is the primary determinant of the curative po-
tential for surgical intervention. For a delay in intervention
to be harmful, it must permit dissemination and not just
growth of the primary tumor. Recent evidence demonstrates
that early metastases are not detectable with standard patho-
logic examination.6,7 Thus early dissemination is unlikely to
be apparent to the pathologist, and patients with early dis-
semination will be classified as having pathologic early
stage disease. Presumably, these are the patients who will
die of recurrent cancer despite “curative” operations. If a
delay in surgical intervention permits tumor dissemination,
then the effect of delay on prognosis should be most appar-
ent for patients with resected pathologic early stage disease.
The goal of this study was to determine whether the
length of time between detection and resection of early
stage lung cancers correlates with survival.
Material and Methods
The Committee on Human Research of the University of Califor-
nia, San Francisco, and the Institutional Review Board of the San
Francisco VA Medical Center reviewed and approved this study.
Records from the San Francisco VA Medical Center from 1989 to
1999 were reviewed. Charts of patients who underwent surgical
intervention for pathologic stage I or II NSCLC were abstracted
for patient age, race, sex, medical history, date of presentation,
date and type of surgical treatment, pathologic stage, cause of
death, and date of death or last follow-up. Date of presentation was
defined as the earliest date at which the pulmonary lesion could
have been identified. The preoperative interval (delay) was defined
as the time between presentation and the operation.
Survival was defined in 2 ways. First, it was defined as the time
from surgical intervention to death or last follow-up. This method
is the cleanest from a statistical standpoint, but it introduces the
possibility of lead-time bias: the survival of patients with long
delays between presentation and surgical intervention does not
include the preoperative waiting time and therefore might be
artificially short. To address this issue, we also performed land-
mark analyses in which time is counted from the date of presen-
tation, but the length of delay is assessed at a point (landmark) a
fixed number of days after presentation. For these analyses, pa-
tients who died or were censored before the landmark (90 days) are
regarded as noninformative.
Kaplan-Meier survival analysis was performed (SAS, version
6.12; SAS, Inc, Cary, NC), and log-rank analyses were used to test
for the effect of delay on survival. The effect of delay on survival
was first analyzed by using delay as a single, continuous variable.
In a second analysis patients were divided into 2 groups on the
basis of the length of preoperative delay (90 days or 90 days),
and survival between the groups was compared. For analysis of
disease-specific survival, patients who died from causes unrelated
to their lung cancer were censored at the time of death.
Results
Patient Characteristics
From 1989 through 1999, 84 patients underwent surgical
intervention for pathologic stage I or II NSCLC, 46 within
90 days of presentation and 38 at least 90 days after pre-
sentation (Table 1). Median age at presentation was 66
years, and 95% of the patients were men. Thirty-eight
percent had hypertension, 30% had coronary artery disease,
and 54% had emphysema. Fifty-six (66.7%) patients had
right-sided cancers. There were 84 operations in 84 patients.
Right upper lobectomy was the most common procedure,
and 14 patients underwent pneumonectomy. Adenocarcino-
mas were slightly more common than squamous cell carci-
nomas, and the remaining tumors were large cell carcino-
mas. Fifty-nine (70%) patients had pathologic stage I
disease.
Preoperative Delay
Time from detection of the pulmonary lesion to surgical
intervention ranged from 1 to 641 days, with a median of 82
days and a mean of 126 days. Delay was greater than 200
days for 14 patients. Of these, 4 had no documentation of
the reason for delay. For the remaining 10 patients, delay
was attributed to treatment of comorbidities, patient deci-
sion making, retrospective detection, observation with serial
films, and delays in transferring patients and patient infor-
mation from referring hospitals.
Survival Analysis
Median follow-up after surgical intervention was 3.3 years
(range, 5 days-11.9 years). Forty-two (50%) patients were
alive at the time of analysis. Of the 42 patients who died, 21
(50%) died of documented metastatic lung cancer. One
patient died from metastatic adenocarcinoma that might
have arisen from either his lung or his colon cancer. There
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were 3 perioperative deaths. Two (2.4%) patients died
within 30 days of surgical intervention: one from intraop-
erative bleeding and one from respiratory failure on post-
operative day 4. One patient died from respiratory failure 44
days after surgical intervention. Eighty-three percent (35/
42) of the patients who died did so within 4 years of
presentation.
Overall 5-year survival was 40%, and median survival
was 3.7 years (Figure 1, A). Log-rank analysis demonstrated
no significant effect of preoperative delay on postoperative
survival (P  .54). The estimated hazard ratio for a 90-day
increment in delay was 1.06 (95% confidence interval [CI],
0.87-1.30). We also carried out an analysis in which delay
was dichotomized at 90 days. This time interval is close to
the median for our population and also represents a standard
waiting time between serial radiographic evaluations of a
patient with a low-suspicion pulmonary nodule. We found
no significant difference in the postoperative survival be-
tween these 2 groups (P  .78; Figure 1, B).
A landmark analysis was performed in which survival
was calculated from the date of presentation instead of the
date of surgical intervention to address the potential prob-
lem of lead-time bias. With this modification, analysis did
not show a significant effect of delay on survival (P  .66;
Figure 2, A). The hazard ratio for failure to undergo an
operation by the 90-day landmark was 0.87 (95% CI, 0.47-
1.61). Similarly, when preoperative delay was dichoto-
mized, there was no significant difference in survival be-
tween the 2 groups (P  .45; Figure 2, B).
Data were also analyzed by using disease-specific sur-
vival as the end point. Patients who died of causes unrelated
to lung cancer were censored at the time of death. Five-year
disease-specific survival, measured from the date of the
operation, was 63% (Figure 3, A). The effect of preoperative
delay on survival was not significant, either as a continuous
variable or when patients were divided into 2 groups on the
basis of a delay of 90 days (Figure 3, B). Landmark analyses
of these data also demonstrated no significant effect.
TABLE 1. Patient characteristics by duration of preopera-
tive delay
<90-d delay >90-d delay
Total No. 46 38
Sex
Male 43 37
Female 3 1
Median age (y) 63 68
Tumor location
Right 33 23
Left 13 15
Procedure
Wedge 1 5
Lobe 40 24
Pneumonectomy 5 9
Histology
Adeno 20 20
Squamous 21 4
Large cell 5 14
Pathologic stage (AJCCS)
1A 11 17
1B 18 13
2A 2 1
2B 15 7
Comorbidity
Emphysema 26 19
CAD 12 13
Hypertension 16 16
DM 6 8
Other malignancy
GI 4 4
GU 4 4
H&N 3 3
Lung 2 0
Other 3 3
AJCCS, American Joint Committee on Cancer Staging; CAD, coronary
artery disease; DM, diabetes mellitus; GI, gastrointestinal; GU, genitouri-
nary; H&N, head and neck.
Figure 1. Overall survival from the date of surgical intervention. A,
Survival for all patients as a single group: correlation between
survival and preoperative delay as a continuous variable was not
significant (P .54; hazard ratio of 1.06 and 95% CI of 0.87-1.30 for
a 90-day increment in delay). B, Survival for patients grouped by
duration of preoperative delay (solid line, <90 days; dashed line,
>90 days): difference by log rank was not significant (P  .78).
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Discussion
Patients with known or suspected early stage lung cancer
should proceed expeditiously through evaluation, staging,
and surgical intervention, but for some patients with an
indeterminate lung nodule, repeat imaging 3 months later is
an acceptable alternative. The increasing use of spiral CT8
to screen for early lung cancers will dramatically increase
the number of patients found to have indeterminate pulmo-
nary nodules, and the appropriate management of these
patients is unclear. The desire to avoid delay in therapy
prompts some clinicians to advocate resection of these
nodules soon after their detection, but it is questionable that
such an aggressive approach will improve survival. Further-
more, this strategy will expose many patients with benign
disease to the expense and morbidity of unnecessary testing
and operations. Concern that delay in surgical intervention
might worsen prognosis is also a factor in some clinicians’
resistance to the use of neoadjuvant therapy for patients
with early stage lung cancer.
Studies of tumor biology indicate that even the smallest
lung cancers have been present for many years before
becoming clinically apparent. How critical, then, is it to
proceed quickly to surgical intervention, and how detrimen-
tal is it for there to be a relatively brief period of delay
associated with either observation or preoperative therapy?
A large prospective randomized trial would be necessary to
conclusively answer this question, but such a trial is un-
likely. As an alternative, we chose a retrospective analysis
of all patients who underwent operations for early stage
NSCLC at a single institution. This population experienced
a broad range of delay between when the tumor first became
apparent and when it was resected. Our results do not
demonstrate that an increasing interval between detection
and surgical intervention affected survival.
The patients included in this series are similar in many
respects to the larger population of all patients with lung
cancer. Smoking history, age, histology, and lobar distribu-
Figure 2. Overall survival from date of presentation. A, Survival for
all patients as a single group: correlation between survival and
preoperative delay as a continuous variable was not significant
(P  .66; hazard ratio of 0.87 and 95% CI of 0.47-1.61 for a 90-day
increment in delay). B, Survival for patients grouped by duration
of preoperative delay (solid line, <90 days; dashed line, >90
days): difference by log rank was not significant (P  .45).
Figure 3. Cancer-related survival from the date of surgical inter-
vention. Patients who died from causes other than lung cancer
were censored at the time of death. A, Survival for all patients as
a single group: correlation between survival and preoperative
delay as a continuous variable was not significant (P  .64). B,
Survival for patients grouped by duration of preoperative delay
(solid line, <90 days; dashed line, >90 days): difference by log
rank was not significant (P  .23).
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tion of disease are all representative of the population at
large. Consistent with a VA population, however, 95% were
men. Survival also differed from the expected value and was
only 40% at 5 years, which is lower than anticipated for a
mixture of patients with stage I and II disease. This probably
reflects the high incidence of significant comorbidity in the
veteran population: 39 (46%) patients had a second malig-
nancy, and only 21 of the 42 deaths were attributable to
documented recurrent lung cancer. When deaths unrelated
to lung cancer are censored, long-term survival compares
favorably with historical results.
Christensen and colleagues9 also examined the effect of
delay in therapy on survival. They collected retrospective
data for 172 patients and found that the time from presen-
tation to initiation of treatment was longer for those with
stage III or IV disease than for those with stage I or II
disease. From this, they concluded that delay in therapy
increased the risk of disease progression. However, it is not
clear that disease stage at presentation was comparable
between the 2 groups. Longer delays in the advanced-stage
group might be attributable to a more extensive diagnostic
and metastatic work-up and therefore might be the result
and not the cause of the advanced stage. Importantly, Chris-
tensen and colleagues found that median delay for patients
with stage I or II disease was 3 months, which is similar to
the median delay for patients in our series.
Others have approached the question of the effect of
preoperative delay by using tumor size as a surrogate for
time. The size criterion for distinction between T1 and T2
tumors implies that larger tumors carry a worse prognosis,
and hence some argue that delaying surgical intervention
while the patient’s tumor grows risks worsening prognosis.
Koike and associates10 reviewed 496 patients who under-
went operations for clinical stage IA NSCLC. They found
that tumors 2.0 cm or less in diameter were associated with
a better prognosis than tumors of 2.1 to 3.0 cm in diameter.
In contrast, Patz and coworkers11 concluded from their
retrospective series of 510 patients with pathologic stage IA
disease that tumor size did not correlate with survival.
Regardless, these results might not be applicable to the
effect of a prolonged preoperative interval on prognosis for
individual patients. For this extrapolation to be valid, two
assumptions must be true. First, larger tumors must have
grown from smaller ones, and second, when the larger
tumors were of equivalent size to the smaller ones, they
must have had equivalent biologic behavior. Although the
former assumption is certainly true, the latter likely is not:
larger tumors might present as larger tumors because they
are more aggressive and not simply because they are older.
Furthermore, any survival analysis in which these groups
are compared is subject to lead-time bias: if the larger
tumors are older, then the patients’ survival after surgical
intervention necessarily will be shorter.
There are important limitations to this retrospective anal-
ysis. First, the inclusion of only patients with pathologic
early stage disease might have excluded from analysis pre-
cisely those who suffered most from a delay: patients who
progressed from early to advanced stage while awaiting
surgical intervention. Although this possibility cannot be
excluded, we believe that including only patients with early
stage disease is the most effective way to concentrate on
patients who might have experienced the transition from
truly localized to disseminated disease. Early metastases
should be pathologically occult. Recent work with detection
of micrometastases12 and occult disease3,13,14 support the
hypothesis that disease progression involves dissemination
of tumor cells well before metastases are apparent by means
of standard pathologic examination. Therefore standard pa-
thology for patients with early tumor dissemination is un-
likely to detect this early phase of metastasis, and patients
who experienced the transition from localized to dissemi-
nated disease would continue to have pathologically early
stage disease for some time.
Limiting a review to only patients with pathologically
early stage disease does include patients whose primary
tumor might have progressed from T1 to T2 by virtue of
invasion of the visceral pleura. This event should be con-
sidered a risk factor for dissemination, and its effect on
survival, if any, should be reflected in a study of patients
with pathologic early stage disease.
A second limitation of this study is sample size. Our
study is small, and the 95% CIs for calculated hazard ratios
are broad. This indicates that the lack of statistical signifi-
cance might reflect a type II error. With 42 deaths and 42
patients alive or lost to follow-up, our study has an 80%
power to detect a hazard ratio of 2.38. To illustrate this
value, if overall survival is 40%, then survival in the high-
risk and low-risk groups must be 55% and 24%, respec-
tively, for the difference to achieve statistical significance.
For this study to have sufficient power (80%) to detect a
hazard ratio of 1.5 (overall survival, 40%; low risk, 47%;
high risk, 32%), a minimum of 166 patients in each group,
with complete follow-up, is required.
Surgical intervention remains the most effective therapy
for patients with early stage lung cancer, indicating that
resection must deprive localized tumors of the opportunity
to disseminate, but survival statistics, tumor biology, and
studies of occult disease suggest that a reasonable delay in
time to surgical intervention might not affect tumor dissem-
ination. Our series is small, and similar analyses of larger
groups of patients are needed, but our results should be
thought provoking and hopefully will stimulate us to recon-
sider the value of observation as a diagnostic tool. Renewed
interest in screening15-19 and widespread use of spiral CT
will identify many patients with indeterminate pulmonary
nodules. This will make it increasingly important for us to
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be willing to forego an expensive diagnostic work-up and
prompt resection in favor of confident reassurance and
prudent observation. In this regard the novel use of com-
puter algorithms to assess small changes in tumor volume
over relatively brief periods of time is an exciting develop-
ment.20
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Discussion
Dr John Benfield (Los Angeles, Calif). Dr Quarterman and col-
leagues reviewed their 9-year experience with 84 patients with
stage I and II lung cancer whose median follow-up was about 3.6
years to assess whether delays between detection and resection
influenced outcomes. It is not surprising that outcomes were inde-
pendent of the alacrity of definitive therapy in light of what we
know about cancer biology. However, such observations have on
occasion been carried to absurdity, with the contention that treat-
ment is only a passing event in the natural history of the neoplasm,
and in clinical practice each of us can cite many harmful examples
of procrastination. Two things are important: in some cases resec-
tion is the only treatment that is curative, and in all cases patients
and their families view the diagnosis of lung cancer as an emer-
gency. Dr Quarterman’s findings support the practice of reassuring
anxious patients and their families to the effect that a scheduled
delay between diagnosis and treatment will do no harm. However,
I believe it would be pushing the clock back decades, and a pity,
if Dr Quarterman’s findings were used to justify procrastination.
Judicious observation has always been an option that each of us
recommends occasionally, but in my judgement resection of an
indeterminate lung lesion remains the most conservative manage-
ment that can be recommended for an indeterminate lung lesion.
In their thoughtful article Quarterman and associates appropri-
ately discuss the limitations of their report. I want to add the
limitation that their selection of 82 days as the cutoff point be-
tween timely and delayed resection is understandable but artificial.
In practice, about 10 days should be the cutoff point between
delayed and prompt treatment. Having said this, I readily concede
that it is unlikely that a different cutoff point would have changed
their findings. Much more important is our limited and still prim-
itive ability to assess the behavior of cancers (ie, tumor biology).
The keys to predicting the behavior of cancers and to having
data on which to base rational and effective systemic treatments
surely lie in the genomic area. This is illustrated in embryonic
fashion by many ongoing studies of oncogenes and tumor sup-
pressor genes and gene therapy. The future is exciting, and I am
very happy for young surgeons who are at the beginning of their
research careers.
I predict that some years from now Dr Quarterman and col-
leagues will be reporting about time intervals from detection to
resection only in passing. Instead, they will correlate cytogenetic
data, tumor markers, and immunologic modifiers with treatment
outcomes. The work-up of each patient will include assessment of
genetic profiles of his or her cancer. Eventually, we will also have
measures of host resistance of each patient. Armed with such
information, multimodality treatment planning, often including
surgical intervention, will become more effective than today’s
management.
This has been a useful report, particularly because it is the
beginning of larger studies, presumably in the framework of co-
operative trials. Dr Quarterman, would you please tell us what you
have in mind and how far you have progressed toward the exten-
sion of your work?
Dr Quarterman. Thank you. Our current plan is to set up
collaborations with other VA medical centers. The VA database is
very advantageous because there are several centers within it.
Also, there is a tumor registry with centralized information from
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which we can begin analysis. Third, VA centers are beginning to
have a more regimented documentation and charting process,
which will make abstracting data and interpreting data easier.
We are also starting up some studies in molecular biology to
begin to evaluate tumor markers for staging and possible predic-
tion of prognosis, with the expectation that in the future, that type
of information will make the question of preoperative delay un-
necessary.
Dr Steven Guyton (Seattle, Wash). I am concerned about your
point of time for patient selection because you have identified a
group of patients with good prognoses. Did you make any attempt
to go back and find patients who presented with pulmonary nod-
ules who then turned out to have more advanced disease?
Dr Quarterman. Yes. We decided to exclude patients who
ended up having pathologic stage III or IV disease because our
interest was in evaluating patients who began with localized dis-
ease. With the knowledge of tumor biology, it is expected that
patients who have disseminated disease with micrometastases
would have such metastases that are not detectable pathologically,
and our interest was in picking up patients who started out with
localized disease and progressed to disseminated disease. It was
believed that if we evaluated patients who had stage III or IV
disease at the time of the operation, it was likely that they began
with a disease that was beyond being localized in the first place.
Dr Douglas Wood (Seattle, Wash). I think that your article is
a valuable one and gives us some justification for the occasional
patient that we do observe and for giving some reassurance to
those patients. I have just come from a meeting at the National
Cancer Institute of screening in lung cancer attended by radiolo-
gists, pathologists, and surgeons. The radiologists now believe,
and I think that they are right, that the indeterminate nodule is now
almost nonexistent and that with the types of CT scans that we
have today and the ability to analyze them on the basis of CT
criteria and with positron emission tomography imaging, that truly
we have the characteristics that we need to determine whether a
nodule can be observed or resected. What percentage of the nod-
ules do you think, with the imaging that we have today, are truly
indeterminate and would fall in this category that we would
follow? I agree with Dr Benfield that the majority of the nodules
are interpretable and should be resected.
Dr Quarterman. I think that is a good point, and in fact,
most of the nodules that would be detected in this day and age
would cause care teams to get further evaluation, and most
likely, a very small percentage of them are actually nonmalig-
nant or of no consequence. Nonetheless, I think that our find-
ings continue to bring up the concept of watchful observation
and to keep in mind that such a technique is still possibly valid
in evaluating nodules, such that instead of going straight to
fine-needle aspiration, serial observations with radiographic
studies could still be possible without being detrimental to the
patients.
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